Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to $384000.0.

  • C4 Therapeutics' Depreciation and Depletion rose 520.55% to $384000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 1861.86%. This contributed to the annual value of $1.5 million for FY2024, which is 665.4% down from last year.
  • As of Q3 2025, C4 Therapeutics' Depreciation and Depletion stood at $384000.0, which was up 520.55% from $416000.0 recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Depreciation and Depletion registered a high of $545000.0 during Q1 2023, and its lowest value of $128000.0 during Q4 2023.
  • Its 5-year average for Depreciation and Depletion is $384736.8, with a median of $384000.0 in 2025.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first crashed by 7543.19% in 2023, then soared by 18437.5% in 2024.
  • Quarter analysis of 5 years shows C4 Therapeutics' Depreciation and Depletion stood at $323000.0 in 2021, then skyrocketed by 61.3% to $521000.0 in 2022, then tumbled by 75.43% to $128000.0 in 2023, then surged by 184.38% to $364000.0 in 2024, then increased by 5.49% to $384000.0 in 2025.
  • Its Depreciation and Depletion was $384000.0 in Q3 2025, compared to $416000.0 in Q2 2025 and $364000.0 in Q1 2025.